ASCENTAGE PHARMA GROUP INTERNATIONAL — Investor Relations & Filings

Ascentage Pharma Group International is a global, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for cancers, chronic hepatitis B, and age-related diseases. The company aims to address unmet medical needs by creating first-in-class and best-in-class small-molecule drugs. Its core scientific expertise is in structure-based drug design and targeting key proteins that regulate apoptosis (programmed cell death). The company's pipeline features multiple drug candidates being evaluated in numerous clinical studies globally. Key assets include olverembatinib, a third-generation BCR-ABL inhibitor; lisaftoclax (APG-2575), a selective Bcl-2 inhibitor; and pelcitoclax (APG-1252), a dual Bcl-2/Bcl-xL inhibitor. These candidates have received multiple Fast Track, Orphan Drug, and Rare Pediatric Disease designations from global regulatory authorities.